OUR TECHNOLOGY

Feature of the Technology

1Novel adjuvant for more potent immune response

The adjuvant was screened from TLR3 library using in vivo DC activation as exemplified in next diagram.

The adjuvant for nasal influenza vaccine

  • The single intranasal vaccination of the adjuvant mixture with inactivated influenza virus protects the mice from lethality.
  • The adjuvant potentiates a strong mucosal immunity.

The novel adjuvant potentiates a nasal influenza vaccine

  • Female Balb/c mice (7 wk-old), 5 mice per group
  • Flu Vac : inactivated mouse-adapted PR8 (A/H1N1)
  • Vaccination by a single nasal drop
  • Vaccination : 0.5 ㎍ Flu Vac + 5 ㎍ Flu Vac + 5 ㎍ adjuvant/ 0.5 ㎍ Flu Vac + 5 ㎍ poly(I:C)
  • Virus challenge (IN) : 100MLD50 mouse-adapted PR8 at 3 weeks after vaccination

The adjuvant for cross reactive vaccines by a nasal delivery

  • The single intranasal vaccination of the adjuvant mixture with inactivated influenza virus protects the mice from lethality.
  • Vaccination with H1N1 inactivated virus protects from lethality by H3N2 viral challenge.

Cross Protective Efficacy (17AF01)

  • Female Balb/c mice (7 wk-old)
  • Adjuvant; 0.1, 0.5, 2.5, and 5 ug
  • Vaccination : 0.5 ㎍ inactivated vaccine A/H1N1 combined with 0.1, 0.5, 2.5 and 5.0 ㎍ adjuvant per head
  • Virus challenge (IN) : 50 PFU of mouse-adapted A/Hong King/8/68 (A/H3N2) at 3 weeks after treatment

Results

The nasal vaccination with 0.5 ㎍ of A/H1N1 vaccine with 5.0 ㎍ adjuvant completely protects mice from the infection of A/H3N2.

The adjuvant for the potent cancer vaccine

  • The adjuvant potentiates therapeutic effect of cancer vaccine.
  • The cytotoxic immune activation is Th-1 system mediated.
  • The mixture of a cancer antigen and the adjuvant can be used in personalized cancer therapy.

The adjuvant for the potent cancer vaccine against metastasis

  • The adjuvant potentiates the therapeutic effect of cancer vaccine.
  • The mixture of a cancer antigen and the adjuvant can be used in personalized cancer therapy.
  • The mixture can block the metastasis of tumor.
2NexaVAC System™: A novel platform for universal peptide vaccine
  • If the antigen from pathogen is replaced by synthetic peptide epitope, the production of vaccine can be faster, safer, and more cost effective. Lots of studies have been done to discover the pathogen specific epitopes through diverse methods. When the epitopes are supplied to immune system, the epitope is recognized as final product after immune processing, instead of as identity of enemies. There is unmet need to present each epitope as entity of strong immune stimulation. The NexaVAC System™ converting a free epitope to strong immune activator in a nanocomplex format. It is universal and can applied to diverse epitopes originated from cancer neoantigens, pathogens, and allergens. Since the systems also can be loaded with small molecules of hepten or some hormone, the platform can be used for chronic metabolic disease of obesity and high blood pressure and vaccine for drug abuse against nicotine and opioid.
3A cold chain free nasal vaccine
  • When a peptide epitope is combined with NexaVAC System™, it forms a heat stable nano-complex that ignites strong mucosal immunity. It can be kept at ambient temperature and be sent to every corner of world without any cold package. Since it can be inhaled without any help of medical staffs, anyone in the remote area can be accessed to the revolutionary technology without extra cost.

R&D Section

  • Cancer peptide vaccine

    neoepitope based peptide vaccine presented by a nanocomplex

    Breast cancer vaccine
    Colorectal cancer
  • Peptide vaccine for infectious disease

    epitope based peptide vaccine presented by a nanocomplex

    Tuberculosis vaccine
    Influenza vaccine
    HPV vaccine
  • Peptide vaccine for chronic metabolic disorder

    epitope based peptide vaccine presented by a nanocomplex

    Diabetics
    Obesity
    High blood pressure
    Alzheimer
  • Peptide vaccine for allergy

    epitope based peptide vaccine presented by a nanocomplex

    peanut allergy
  • Cancer immuno-therapy

    DC mediated neoepitope priming for
    immuno-therapy

  • Platform development
    NexaVAC System™

    optimization of nanocomplex and peptide
    epitope

  • GMP

    teams for production of adjuvant/peptide
    nanocomplex

  • Rregulatory Affair

    teams for Pre-clinical/IND/Clinical trials
    management